This document discusses urothelial carcinoma (UC), a type of bladder cancer. It provides statistics on UC in the US and India. Risk factors like smoking and occupational exposures are discussed. The drug Durvalumab is approved for treating advanced or metastatic UC. It works by blocking the PD-L1 protein, which inhibits the immune system's ability to fight cancer. Details are given on Durvalumab's mechanism of action, pharmacokinetics, dosage administration, storage, and common adverse reactions.